



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/402,634	03/27/2000	BARBARA RONIKER	CU-2019-RJS	6230
7590	06/24/2004		EXAMINER	
Joseph M Skerpon Banner & Witcoff Ltd 1001 G Street NW Washington, DC 20001-4597			JAGOE, DONNA A	
			ART UNIT	PAPER NUMBER
			1614	

DATE MAILED: 06/24/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT PAPER

06172004

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

The supplemental reply brief filed June 8, 2004 has been entered and considered. The appellant asserts that the examiner refers to the instant specification to shed light on the nature of the instant invention and compare it to the prior art. The examiner is not in agreement. The examiner has used the instant specification to shed light on the nature of the instant invention being claimed and used the prior art only in the rejection of the claims. Page 2, lines 3-9 of the instant specification discloses that the role of inflammation in cardiovascular disease is becoming more understood. Since it is known that anti-inflammatories such as COX-2 inhibitors treat inflammation related vascular disease and myocardial infarction and since it is known from the teaching of "Merck" that lipid lowering agents reduce the formation of plaque on blood vessels which would lead to the inflammation related vascular disease of the Searle WO Publication, it would have been obvious to one of ordinary skill in the art at the time the invention was made to combine these two agents to treat a vascular disease such as atherosclerosis (a vascular disease). The application has been forwarded to the Board of Patent Appeals and Interferences for decision on the appeal.



MARIANNE C. SEIDEL  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600